Axitinib Implant（Aerie）

阿西替尼（Aerie）

Report date: 2024/01/02 20:03:52

Base Information

Drug NameAxitinib Implant（Aerie）
Drug Alias NameAR-14034AR-14034 SR
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPlatelet-derived growth factor receptor inhibitorsVascular endothelial growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 1 antagonists +[4] 
TargetsVascular endothelial growth factor receptor 1Vascular endothelial growth factor receptor 3Platelet-derived growth factor receptor +[4] 
Therapy Area/IndicationsMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAerie Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAlcon
Inactive CompaniesN/A
Active IndicationsMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A